These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

985 related articles for article (PubMed ID: 32374571)

  • 1. Neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease: current topics.
    Fujihara K; Cook LJ
    Curr Opin Neurol; 2020 Jun; 33(3):300-308. PubMed ID: 32374571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency of New Silent MRI Lesions in Myelin Oligodendrocyte Glycoprotein Antibody Disease and Aquaporin-4 Antibody Neuromyelitis Optica Spectrum Disorder.
    Camera V; Holm-Mercer L; Ali AAH; Messina S; Horvat T; Kuker W; Leite MI; Palace J
    JAMA Netw Open; 2021 Dec; 4(12):e2137833. PubMed ID: 34878547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort.
    Dauby S; Dive D; Lutteri L; Andris C; Hansen I; Maquet P; Lommers E
    Acta Neurol Belg; 2022 Feb; 122(1):135-144. PubMed ID: 34097296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Blood-brain barrier breakdown and peripheral plasmablasts.
    Tanaka S; Hashimoto B; Izaki S; Oji S; Fukaura H; Nomura K
    Mult Scler Relat Disord; 2020 Jun; 41():102005. PubMed ID: 32114369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
    Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
    J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies.
    Chang X; Huang W; Wang L; ZhangBao J; Zhou L; Lu C; Wang M; Yu J; Li H; Li Y; Zhao C; Lu J; Quan C
    Front Immunol; 2021; 12():647618. PubMed ID: 33796113
    [No Abstract]   [Full Text] [Related]  

  • 7. Neuromyelitis optica spectrum disorders: still evolving and broadening.
    Fujihara K
    Curr Opin Neurol; 2019 Jun; 32(3):385-394. PubMed ID: 30893099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders.
    Ringelstein M; Ayzenberg I; Lindenblatt G; Fischer K; Gahlen A; Novi G; Hayward-Könnecke H; Schippling S; Rommer PS; Kornek B; Zrzavy T; Biotti D; Ciron J; Audoin B; Berthele A; Giglhuber K; Zephir H; Kümpfel T; Berger R; Röther J; Häußler V; Stellmann JP; Whittam D; Jacob A; Kraemer M; Gueguen A; Deschamps R; Bayas A; Hümmert MW; Trebst C; Haarmann A; Jarius S; Wildemann B; Grothe M; Siebert N; Ruprecht K; Paul F; Collongues N; Marignier R; Levy M; Karenfort M; Deppe M; Albrecht P; Hellwig K; Gold R; Hartung HP; Meuth SG; Kleiter I; Aktas O;
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34785575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leptomeningeal Enhancement in Pediatric Anti-Myelin Oligodendrocyte Glycoprotein Antibody Disease, Multiple Sclerosis, and Neuromyelitis Optica Spectrum Disorder.
    Goldman-Yassen A; Lee A; Gombolay G
    Pediatr Neurol; 2024 Apr; 153():125-130. PubMed ID: 38382244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype.
    Kitley J; Woodhall M; Waters P; Leite MI; Devenney E; Craig J; Palace J; Vincent A
    Neurology; 2012 Sep; 79(12):1273-7. PubMed ID: 22914827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Grey Matter Atrophy and its Relationship with White Matter Lesions in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder, and Multiple Sclerosis.
    Cortese R; Battaglini M; Prados F; Gentile G; Luchetti L; Bianchi A; Haider L; Jacob A; Palace J; Messina S; Paul F; Marignier R; Durand-Dubief F; de Medeiros Rimkus C; Apostolos Pereira SL; Sato DK; Filippi M; Rocca MA; Cacciaguerra L; Rovira À; Sastre-Garriga J; Arrambide G; Liu Y; Duan Y; Gasperini C; Tortorella C; Ruggieri S; Amato MP; Ulivelli M; Groppa S; Grothe M; Llufriu S; Sepulveda M; Lukas C; Bellenberg B; Schneider R; Sowa P; Celius EG; Pröbstel AK; Granziera C; Yaldizli Ö; Müller J; Stankoff B; Bodini B; Barkhof F; Ciccarelli O; De Stefano N;
    Ann Neurol; 2024 Aug; 96(2):276-288. PubMed ID: 38780377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
    Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
    Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies.
    Zhao-Fleming HH; Valencia Sanchez C; Sechi E; Inbarasu J; Wijdicks EF; Pittock SJ; Chen JJ; Wingerchuk DM; Weinshenker BG; Lopez-Chiriboga S; Dubey D; Tillema JM; Toledano M; Yadav H; Flanagan EP
    Neurology; 2021 Sep; 97(13):e1351-e1358. PubMed ID: 34389648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease.
    Barreras P; Vasileiou ES; Filippatou AG; Fitzgerald KC; Levy M; Pardo CA; Newsome SD; Mowry EM; Calabresi PA; Sotirchos ES
    Neurology; 2022 Nov; 99(22):e2504-e2516. PubMed ID: 36240094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients.
    Hamid SHM; Whittam D; Mutch K; Linaker S; Solomon T; Das K; Bhojak M; Jacob A
    J Neurol; 2017 Oct; 264(10):2088-2094. PubMed ID: 28840314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
    Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
    JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seizures and epilepsy in multiple sclerosis, aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody-associated disease.
    Li EC; Zheng Y; Cai MT; Lai QL; Fang GL; Du BQ; Shen CH; Zhang YX; Wu LJ; Ding MP
    Epilepsia; 2022 Sep; 63(9):2173-2191. PubMed ID: 35652436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease.
    Akaishi T; Misu T; Fujihara K; Takahashi T; Takai Y; Nishiyama S; Kaneko K; Fujimori J; Ishii T; Aoki M; Nakashima I
    J Neurol; 2022 Jun; 269(6):3136-3146. PubMed ID: 34820735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What You Need to Know About AQP4, MOG, and NMOSD.
    Prasad S; Chen J
    Semin Neurol; 2019 Dec; 39(6):718-731. PubMed ID: 31847043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.